Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study
Creative Medical Technology highlighted six-month data from a 30-patient study of its Ultrasome™ cell-free regenerative platform in knee osteoarthritis, with 28 of 30 patients (93%) meeting study-defined response criteria. Average pain scores fell approximately 65% from baseline, WOMAC scores declined 52%, and no serious adverse events were reported during follow-up.
Key figures
- Drug Name
- Ultrasome™
- Phase Of Trial
- open-label, single-arm pilot study
- Patients enrolled
- 30
- Patients responding
- 28
- Pain score reduction
- 65%
- Patient response rate
- 93%
- Study duration months
- 6
- Womac score reduction
- 52%
- Quality of life improvement
- approximately 35 points
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.